Regeneron, a US pharmaceutical company, has acquired UK biotech company Oxular, which specialises in the development of treatments for retinal diseases. Through the acquisition, Regeneron intends to expand its ophthalmology portfolio.

Thedeal will include Oxular’s exclusive ocular delivery technology as well as its Phase 2 therapy, OXU-001; both of which are currently being explored for the treatment of diabetic macular oedema. OXU-001 is a gene therapy which delivers anti-VEGF agents directly to the retina.